Loading...
Market
Story
FDA Approves Rybrevant for EGFR-Mutated Lung Cancer in US, Reducing Progression Risk by Over 50%
Sep 20, 2024, 09:56 AM
Rybrevant (amivantamab-vmjw) has been approved by the FDA for the treatment of second-line EGFR-mutated advanced lung cancer in the US. This approval marks the first and only targeted regimen to cut the risk of disease progression by more than 50% when used in combination with standard care. This significant development is expected to help Johnson & Johnson move closer to its $5 billion sales target for Rybrevant. The approval specifically applies to patients with EGFR ex19del/L858R substitution mutations who have progressed on or after EGFR TKI treatment. Notably, this is the third new indication for Johnson & Johnson in 2024.
View original story
Similar markets
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5% to 10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
